Patient Experience Report: Volume 1

GLP-1 RA and SGLT2-I Adoption and Retention in Patients with Diabetes

We've tapped into the largest and most clinically representative diabetes patient database in the US, comprising over 60,000 individuals living with diabetes. This report unveils the reasons behind patient decisions regarding the starting, switching, and stopping of GLP-1 RA and SGLT2-I treatments.

What you get

Reliable data empowering your organization to confidently make strategic decisions. This report includes insights from:
  • 1,500+ US adults with type 2 diabetes

  • 40% non-white participants

  • 50% male / 50% female respondents